Loading...
Docoh

Aligos Therapeutics (ALGS)

Utility
Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
9 Jun 22
Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof.
Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
Filed: 15 Feb 22
Utility
Tricyclic Compounds
2 Jun 22
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, Yannick Debing, Pierre Jean-Marie Bernard Raboisson
Filed: 22 Nov 21
Utility
Conjugates of S-antigen Transport Inhibiting Oligonucleotide Polymers Having Enhanced Liver Targeting
26 May 22
Disclosed herein is an oligonucleotide conjugate or complex thereof, comprising a modified oligonucleotide having sequence independent antiviral activity against hepatitis B, a liver targeting agent, and a linker connecting the liver targeting agent to a 3′ end and/or a 5′ end of the modified oligonucleotide or complex thereof.
Leonid Beigelman, Megan Elizabeth Fitzgerald, Rajendra Pandey, Jin Hong, Vivek Kumar Rajwanshi, David Bernard Smith, Lawrence M. Blatt
Filed: 18 Nov 21
Utility
Oxindoles and Methods of Use Thereof
12 May 22
David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
Filed: 5 Nov 21
Utility
2-PYRIDONES and Methods of Use Thereof
12 May 22
David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
Filed: 5 Nov 21
Utility
Bicyclic Pyridazinones and Methods of Use Thereof
12 May 22
David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
Filed: 5 Nov 21
Utility
S-antigen Transport Inhibiting Oligonucleotide Polymers and Methods
28 Apr 22
Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions.
Leonid Beigelman, Rajendra Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Lawrence M. Blatt, Jin Hong
Filed: 26 Oct 21
Utility
Bicyclic Compounds
21 Apr 22
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, Pierre Jean-Marie Bernard Raboisson, David McGowan
Filed: 19 Oct 21
Utility
Bicyclic Compounds
21 Apr 22
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, Yannick Debing, Antitsa Dimitrova Stoycheva, Pierre Jean-Marie Bernard Raboisson
Filed: 13 Oct 21
Utility
Compounds Targeting PRMT5
14 Apr 22
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing, Francois Gonzalvez
Filed: 30 Mar 21
Utility
Pyrrole Compounds
10 Mar 22
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, Vladimir Serebryany, Raymond F. Schinazi, Franck Amblard, Leda Bassit
Filed: 16 Nov 21
Utility
HBV Binding Oligonucleotides and Methods of Use
24 Feb 22
Oligonucleotides that target hepatitis B virus (HBV) viral sequences, such as rcDNA, cccDNA, and HBV transcripts, are described herein.
Jin Hong, Leonid Beigelman, Aneerban Bhattacharya, N. Tilani S. De Costa
Filed: 26 Jul 21
Utility
Compounds Targeting PRMT5
17 Feb 22
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
Filed: 28 Oct 21
Utility
Modulators of Thr-beta and Methods of Use Thereof
13 Jan 22
David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval
Filed: 8 Jul 21
Utility
Anti-viral Compounds
13 Jan 22
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Vladimir Serebryany, Antitsa Dimitrova Stoycheva, Dorothée Alice Marie-Eve Bardiot, Sandro Boland, Arnaud Didier Marie Marchand
Filed: 8 Jun 21
Utility
Tricyclic Compounds
6 Jan 22
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville
Filed: 1 Sep 21
Utility
Compounds targeting PRMT5
14 Dec 21
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
Filed: 31 Mar 20
Utility
Pyrrole compounds
7 Dec 21
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, Vladimir Serebryany
Filed: 1 Apr 20
Utility
Modulators of Thr-beta and Methods of Use Thereof
18 Nov 21
Koen Vandyck, Pierre Jean-Marie Bernard RABOISSON, David McGowan, Jerome Deval
Filed: 25 May 21
Utility
S-antigen transport inhibiting oligonucleotide polymers and methods
9 Nov 21
Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions.
Leonid Beigelman, Rajendra Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Lawrence M. Blatt, Jin Hong
Filed: 11 Sep 20
Patents are sorted by USPTO publication date, most recent first